Phase 1 Dose-Escalation Study of Multiple Dosing Schedules of the Investigational Drug MLN4924, a Nedd8-Activating Enzyme Inhibitor, In Patients with Relapsed and/or Refractory Multiple Myeloma or Lymphoma

被引：0
|
作者：
Shah, Jatin J. [1 ]
Harvey, R. Donald [2 ]
O'Connor, Owen A. [3 ]
Jakubowiak, Andrzej J. [4 ]
Smith, Mitchell R. [5 ]
Orlowski, Robert Z. [1 ]
Mulligan, George J. [6 ]
Smith, Peter G. [7 ]
Pickard, Michael D. [8 ]
Dezube, Bruce J. [9 ]
Lonial, Sagar [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Emory Univ, Winship Cancer Inst, Atlanta, GA 30322 USA
[3] NYU Langone Med Ctr, Dept Med, NYU Canc Inst, New York, NY USA
[4] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[5] Fox Chase Canc Ctr, Lymphoma Serv, Philadelphia, PA 19111 USA
[6] Millennium Pharmaceut Inc, Mol Med, Cambridge, MA USA
[7] Millennium Pharmaceut Inc, Discovery, Cambridge, MA USA
[8] Millennium Pharmaceut Inc, Biostat, Cambridge, MA USA
[9] Millennium Pharmaceut Inc, Oncol Clin Res, Cambridge, MA USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1155 / 1155
页数：1
相关论文
共 50 条
  • [41] MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB-dependent lymphoma
    Milhollen, Michael A.
    Traore, Tary
    Adams-Duffy, Jennifer
    Thomas, Michael P.
    Berger, Allison J.
    Dang, Lenny
    Dick, Lawrence R.
    Garnsey, James J.
    Koenig, Erik
    Langston, Steven P.
    Manfredi, Mark
    Narayanan, Usha
    Rolfe, Mark
    Staudt, Louis M.
    Soucy, Teresa A.
    Yu, Jie
    Zhang, Julie
    Bolen, Joseph B.
    Smith, Peter G.
    BLOOD, 2010, 116 (09) : 1515 - 1523
  • [42] Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer (vol 59, pg 246, 2012)
    Smith, Malcolm A.
    Maris, John M.
    Gorlick, Richard
    Kolb, E. Anders
    Lock, Richard
    Carol, Hernan
    Keir, Stephen T.
    Reynolds, C. Patrick
    Kang, Min H.
    Morton, Christopher L.
    Wu, Jianrong
    Smith, Peter G.
    Yu, Jie
    Houghton, Peter J.
    PEDIATRIC BLOOD & CANCER, 2012, 59 (04) : 772 - 772
  • [43] Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
    Kumar, Shaji K.
    Bensinger, William I.
    Zimmerman, Todd M.
    Reeder, Craig B.
    Berenson, James R.
    Berg, Deborah
    Hui, Ai-Min
    Gupta, Neeraj
    Di Bacco, Alessandra
    Yu, Jiang
    Shou, Yaping
    Niesvizky, Ruben
    BLOOD, 2014, 124 (07) : 1047 - 1055
  • [44] Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study
    Shinsuke Iida
    Kenshi Suzuki
    Shigeru Kusumoto
    Masaki Ri
    Nobuhiro Tsukada
    Yu Abe
    Masayuki Aoki
    Mitsuo Inagaki
    International Journal of Hematology, 2017, 106 : 541 - 551
  • [45] MLN4924, a Novel Small Molecule Inhibitor of Nedd8-Activating Enzyme, Demonstrates Potent Anti-Tumor Activity in Diffuse Large B-Cell Lymphoma
    Milhollen, Michael
    Narayanan, Usha
    Berger, Allison J.
    Thomas, Michael
    Traore, Tary
    Yu, Jie
    Zhang, Julie
    Koenig, Erik
    Garnsey, James J.
    Langston, Steven P.
    Soucy, Teresa A.
    Smith, Peter G.
    BLOOD, 2008, 112 (11) : 226 - 227
  • [46] Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study
    Iida, Shinsuke
    Suzuki, Kenshi
    Kusumoto, Shigeru
    Ri, Masaki
    Tsukada, Nobuhiro
    Abe, Yu
    Aoki, Masayuki
    Inagaki, Mitsuo
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (04) : 541 - 551
  • [47] High expression of CKS1B antagonizes MLN4924, a nedd8-activating enzyme inhibitor, that induces myeloma cell growth inhibition through decreased neddylation of SCF complex
    Zhan, Fenghuang
    Wang, He
    Zangari, Maurizio
    Tricot, Guido
    CANCER RESEARCH, 2012, 72
  • [48] Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study
    Richardson, Paul G.
    Chanan-Khan, Asher A.
    Alsina, Melissa
    Albitar, Maher
    Berman, David
    Messina, Marianne
    Mitsiades, Constantine S.
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (04) : 438 - 445
  • [49] Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): A phase I study.
    Kumar, Shaji
    Bensinger, William
    Reeder, Craig B.
    Zimmerman, Todd M.
    Berenson, James R.
    Liu, Guohui
    Berg, Deborah
    Gupta, Neeraj
    Di Bacco, Alessandra
    Hui, Ai-Min
    Niesvizky, Ruben
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study
    Shah, Jatin J.
    Zonder, Jeffrey
    Cohen, Adam
    Orlowski, Robert Z.
    Alexanian, Raymond
    Thomas, Sheeba K.
    Weber, Donna
    Kaufman, Jonathan L.
    Harvey, R. Donald
    Walker, Duncan
    Litwiler, Kevin
    Karan, Sharon
    Hilder, Brandi
    Ptaszynski, Ann Marie
    Lonial, Sagar
    BLOOD, 2011, 118 (21) : 809 - 810
12345